

Cerecin Sponsors and Presents at Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium

Dr. Samuel Henderson, Cerecin's Chief Scientific Officer, will present rationale and evidence for ketogenic therapies in Alzheimer's disease

SINGAPORE, 11 DECEMBER 2018: Brain health-focused pharmaceutical company Cerecin, today announced that it is a sponsor for the Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium to be held in New York, New York, USA. Dr. Samuel Henderson, Cerecin's Chief Scientific Officer, will present the rationale and evidence for the development of ketogenic therapies in Alzheimer's disease (AD).

The one-day symposium is organized by The New York Academy of Sciences Brain and Behavior Discussion Group and is held today on 11 December 2018. Recognizing that the prevailing focus of Alzheimer's disease drug development on the amyloid cascade hypothesis has not generated new treatments, the Symposium brings together leaders from academic, research and corporate entities, in an effort to connect ideas and find alternative therapeutic targets.

The Symposium will explore new emerging mechanisms that may underly Alzheimer's disease, including mitochondrial dysfunction, vascular disorders, infections, and ketogenic therapies. The induction of ketosis is the foundation of Cerecin's medical food product Axona[®] and lead investigational drug compound *tricaprilin*. In his presentation, Dr. Henderson will introduce the rationale and evidence for ketogenic therapies in Alzheimer's disease.

"Given that there is no cure for Alzheimer's disease and no new therapies have been approved for the past 15 years, it is both necessary and important that we start to look beyond amyloid approaches and spread a wider net to identify new AD drugs." said Dr. Henderson, "It's encouraging to see that the industry is opening up to non-amyloid approaches. At Cerecin we have been investigating the therapeutic potential of ketosis in Alzheimer's for more than a decade and we are glad to share findings with others working on non-amyloid therapies."

Cerecin has recently opened its second headquarters in Singapore due to its unparalleled global infrastructure, world class science and highly skilled work force. "We are delighted to sponsor this important Symposium", said Dr. Charles Stacey, CEO of Cerecin. "The aging demographic in Asia will dramatically increase the prevalence of Alzheimer's Disease in the region over the next 20 years and will present a major health care crisis. Raising awareness of our treatment approach and connecting with researchers working on new ideas will together help us move the field forward."

ENDS

About Cerecin

Cerecin, previously Accera, is a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world. Cerecin is led by an expert executive management team with globally recognized specialists in central nervous system diseases and supported by two partners, Nestlé and Wilmar International. Cerecin's lead compound, *tricaprilin*, is being developed to address the

metabolic deficit that is known to be characteristic of Alzheimer's disease by providing the brain with an alternative energy substrate. Cerecin is currently preparing this newly reformulated compound for global pivotal studies. Bringing together the deep industry expertise of its leadership team and the extensive market access capabilities of its strategic investors, Cerecin is growing its global presence to build a brighter future for Alzheimer's patients.

For more information visit www.cerecin.com.

For further information, please contact:

Emma Thompson/ Jonathan Parry

Spurwing Communications

+65 6340 7287

cerecin@spurwingcomms.com

© 2018 Cerecin AC-18-042 12/18